Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide

A. Filiberti, M. Tamburini, C. Andreoli, F. Buranelli, T. Campa, A. Costa, G. Dossena, A. Magni, M. Pizzichetta, V. Ventafridda

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

One hundred and one patients participating in a phase I study with the synthetic retinoid 4-HPR (4-hydroxyphenyl retinamide) were evaluated. The study was set up by Veronesi et al. during 1986 at the National Cancer Institute of Milan. The patients were randomized into 4 groups of therapy: 25 in the placebo group, 25 in the group receiving a daily dose of 100 mg of HPR, 26 in the group receiving 200 mg/day of HPR, and 25 in the group receiving 300 mg/day of HPR. All patients were previously treated at our Institute for breast cancer. None had received adjuvant therapy, chemotherapy or hormone therapy. After 4-5 months from the beginning of treatment, all patients received a series of tests to evaluate anxiety, depression and sexual life. Moreover, during one the follow-up checkups after 4-5 months, the patients filled-out a self-scoring mood questionnaire. The results did not show any particular differences between the groups, although we found that the administered drug and experimental setting do not interfere with the psychologic state of the participating patients.

Original languageEnglish
Pages (from-to)353-356
Number of pages4
JournalTumori
Volume74
Issue number3
Publication statusPublished - 1988

Fingerprint

Retinoids
National Cancer Institute (U.S.)
Adjuvant Chemotherapy
Group Psychotherapy
retinamide
Therapeutics
Anxiety
Placebos
Hormones
Depression
Breast Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research

Cite this

Filiberti, A., Tamburini, M., Andreoli, C., Buranelli, F., Campa, T., Costa, A., ... Ventafridda, V. (1988). Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide. Tumori, 74(3), 353-356.

Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide. / Filiberti, A.; Tamburini, M.; Andreoli, C.; Buranelli, F.; Campa, T.; Costa, A.; Dossena, G.; Magni, A.; Pizzichetta, M.; Ventafridda, V.

In: Tumori, Vol. 74, No. 3, 1988, p. 353-356.

Research output: Contribution to journalArticle

Filiberti, A, Tamburini, M, Andreoli, C, Buranelli, F, Campa, T, Costa, A, Dossena, G, Magni, A, Pizzichetta, M & Ventafridda, V 1988, 'Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide', Tumori, vol. 74, no. 3, pp. 353-356.
Filiberti A, Tamburini M, Andreoli C, Buranelli F, Campa T, Costa A et al. Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide. Tumori. 1988;74(3):353-356.
Filiberti, A. ; Tamburini, M. ; Andreoli, C. ; Buranelli, F. ; Campa, T. ; Costa, A. ; Dossena, G. ; Magni, A. ; Pizzichetta, M. ; Ventafridda, V. / Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide. In: Tumori. 1988 ; Vol. 74, No. 3. pp. 353-356.
@article{9715a3c74e9d4fbebc0f8e00d6c7768c,
title = "Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide",
abstract = "One hundred and one patients participating in a phase I study with the synthetic retinoid 4-HPR (4-hydroxyphenyl retinamide) were evaluated. The study was set up by Veronesi et al. during 1986 at the National Cancer Institute of Milan. The patients were randomized into 4 groups of therapy: 25 in the placebo group, 25 in the group receiving a daily dose of 100 mg of HPR, 26 in the group receiving 200 mg/day of HPR, and 25 in the group receiving 300 mg/day of HPR. All patients were previously treated at our Institute for breast cancer. None had received adjuvant therapy, chemotherapy or hormone therapy. After 4-5 months from the beginning of treatment, all patients received a series of tests to evaluate anxiety, depression and sexual life. Moreover, during one the follow-up checkups after 4-5 months, the patients filled-out a self-scoring mood questionnaire. The results did not show any particular differences between the groups, although we found that the administered drug and experimental setting do not interfere with the psychologic state of the participating patients.",
author = "A. Filiberti and M. Tamburini and C. Andreoli and F. Buranelli and T. Campa and A. Costa and G. Dossena and A. Magni and M. Pizzichetta and V. Ventafridda",
year = "1988",
language = "English",
volume = "74",
pages = "353--356",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Psychologic aspects of patients participating in a phase I study with the synthetic retinoid 4-hydroxyphenyl retinamide

AU - Filiberti, A.

AU - Tamburini, M.

AU - Andreoli, C.

AU - Buranelli, F.

AU - Campa, T.

AU - Costa, A.

AU - Dossena, G.

AU - Magni, A.

AU - Pizzichetta, M.

AU - Ventafridda, V.

PY - 1988

Y1 - 1988

N2 - One hundred and one patients participating in a phase I study with the synthetic retinoid 4-HPR (4-hydroxyphenyl retinamide) were evaluated. The study was set up by Veronesi et al. during 1986 at the National Cancer Institute of Milan. The patients were randomized into 4 groups of therapy: 25 in the placebo group, 25 in the group receiving a daily dose of 100 mg of HPR, 26 in the group receiving 200 mg/day of HPR, and 25 in the group receiving 300 mg/day of HPR. All patients were previously treated at our Institute for breast cancer. None had received adjuvant therapy, chemotherapy or hormone therapy. After 4-5 months from the beginning of treatment, all patients received a series of tests to evaluate anxiety, depression and sexual life. Moreover, during one the follow-up checkups after 4-5 months, the patients filled-out a self-scoring mood questionnaire. The results did not show any particular differences between the groups, although we found that the administered drug and experimental setting do not interfere with the psychologic state of the participating patients.

AB - One hundred and one patients participating in a phase I study with the synthetic retinoid 4-HPR (4-hydroxyphenyl retinamide) were evaluated. The study was set up by Veronesi et al. during 1986 at the National Cancer Institute of Milan. The patients were randomized into 4 groups of therapy: 25 in the placebo group, 25 in the group receiving a daily dose of 100 mg of HPR, 26 in the group receiving 200 mg/day of HPR, and 25 in the group receiving 300 mg/day of HPR. All patients were previously treated at our Institute for breast cancer. None had received adjuvant therapy, chemotherapy or hormone therapy. After 4-5 months from the beginning of treatment, all patients received a series of tests to evaluate anxiety, depression and sexual life. Moreover, during one the follow-up checkups after 4-5 months, the patients filled-out a self-scoring mood questionnaire. The results did not show any particular differences between the groups, although we found that the administered drug and experimental setting do not interfere with the psychologic state of the participating patients.

UR - http://www.scopus.com/inward/record.url?scp=0023676221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023676221&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 353

EP - 356

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -